Navigation Links
Current and Emerging Therapies Have No Advantage Over Enbrel in Reducing the Signs and Symptoms of Rheumatoid Arthritis

Golimumab Will Earn Decision Resources' Gold Standard for Rheumatoid Arthritis in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., Jan. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed rheumatologists say that a therapy's effect on reducing the signs and symptoms of rheumatoid arthritis at one year is the attribute that most influences their prescribing decisions in treating the disease. Clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage in this attribute over Amgen/Wyeth/Takeda's Enbrel (etanercept), the market sales-leading agent.

The new report entitled Rheumatoid Arthritis: A Novel Oral Therapy Must Satisfy Physicians' High Expectations for Efficacy to Tap Significant Market Opportunity finds that an oral disease-modifying drug with a novel mechanism of action that is priced 20 percent lower than etanercept plus methotrexate would earn a 25 percent patient share in the United States and a 20 percent patient share in Europe, according to surveyed U.S. and European rheumatologists.

Decision Resources' proprietary clinical gold standard in 2008 for rheumatoid arthritis was Enbrel, most notably because of its superior efficacy in inhibiting/slowing structural damage progression at one and two years compared with other agents in the market. Following its approval for the indication, which is likely to occur in 2010, Centocor/Schering-Plough/Mitsubishi Tanabe/Janssen's Simponi (golimumab) will earn Decision Resources' gold standard for rheumatoid arthritis in 2012. Although Simponi's overall efficacy, safety and tolerability do not match that of Enbrel, its advantages in delivery differentiate it from Enbrel.

"Simponi ranks higher than Enbrel on the measures of dosage formulation and dosage frequency," said Decision Resources Analyst Dancella Fernandes, Ph.D. "Simponi offers an alternative formulation and once-monthly dosing compared with Enbrel's once- to twice-weekly dosing. By differentiating itself with improved delivery features, Simponi separates itself in a market crowded with drugs boasting similar efficacy and safety profiles."

About the Report

Rheumatoid Arthritis: A Novel Oral Therapy Must Satisfy Physicians' High Expectations for Efficacy to Tap Significant Market Opportunity is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                             Decision Resources, Inc.
    Christopher Comfort                            Elizabeth Marshall
    781-296-2597                                   781-296-2563              

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
2. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
3. Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors
4. Morris Animal Foundation 2008 Sponsorship Guide Available, Details Current Animal Health Studies
5. Experimental drug boosts survival in recurrent ovarian cancer
6. Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees
7. Stop eating for two: obese moms-to-be should gain less weight than currently recommended
8. Switching to MA Coverage Unlikely for Current Beneficiaries With MediGap or Medicare Only
9. The Current Recall of Boy Scouts of Americas Plastic Badges Does Not Affect Embroidered Insignia, Badges & Awards Produced by Lion Brothers Company Inc.
10. Purified Fish Oil Concentrates Offer Solution to Current Seafood Controversy for Pregnant and Breastfeeding Women!
11. ALEVE-D(R) Sinus & Cold Offers Option for the More Than 50% of Consumers Not Satisfied with Current Sinus Medication
Post Your Comments:
(Date:10/12/2015)... (PRWEB) , ... October 13, 2015 , ... North American ... (IBC) at the 2015 IBC National Meeting in Rosemont, IL on October 4th. ... dedication, quality, and standards of excellence that customers have come to expect from members ...
(Date:10/12/2015)... ... October 12, 2015 , ... ... 19, 2015, high school aged female athletes, particularly in the area of track ... motion and mechanical overuse injuries than male peers in the same age group. ...
(Date:10/12/2015)... ... October 12, 2015 , ... The American Society of Clinical ... professional education and clinical training in a health care discipline. , Many ... such as: losing weight, managing pain, or stopping smoking, etc. Frequently, extravagant statements ...
(Date:10/12/2015)... ... 12, 2015 , ... The Horizon Foundation for New Jersey has awarded $846,600 ... and enhancing the quality of life in the Garden State. The grants, representing the ... , The charitable arm of Horizon Blue Cross Blue Shield of New Jersey, ...
(Date:10/12/2015)... USA (PRWEB) , ... October 12, 2015 , ... ... personal audio products, will present the latest version of Companion Mics, the CM•4 ... audiometry, at the European Union of Hearing Aid Acousticians’ (EUHA) 60th Annual Congress ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... , Oct. 12 2015 ... the addition of the "Personalized Medicine, ... 2019 - Strategic Analysis of Industry Trends, ... their offering. --> ) ... "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ...
(Date:10/12/2015)... -- To help address the growing opioid epidemic in the ... Board of Directors is calling for a comprehensive ... the tracking of opioid prescription use; research funding for ... abuse treatment programs. David Ring , MD, ... "The new , AAOS Information Statement on Opioid Use, ...
(Date:10/12/2015)... Minn. , Oct. 12, 2015 Device ... a need to help integrate these devices into existing ... of ergonomic healthcare mounting and mobility solutions, has launched ... lightest cart yet, for a wide array of laptops ... Cart SV10 was developed exclusively for Microsoft Surface and ...
Breaking Medicine Technology: